Comphya
Providing a better solution for non-responders to oral drugs.
Providing a better solution for non-responders to oral drugs.
Comphya is an innovative medical device startup founded in 2017, specializing in the development of the CaverSTIM device. The company's flagship product, CaverSTIM, utilizes cutting-edge neuroprosthetics expertise to restore erectile function in patients who do not respond to oral drugs. This groundbreaking technology involves implanting a neuro-stimulator in the pelvic cavity to selectively activate the nerve responsible for triggering penile erection. CaverSTIM comprises an implantable pulse generator (IPG), connected to an electrode paddle, external controllers for patients and physicians, and a wireless recharger. The company has garnered significant attention, receiving a Fr.850.00KConvertible Note investment on 31 January 2023 from Praxis Spinal Cord Institute. Comphya operates in the Biotechnology and Health Care industries and holds great potential in addressing an unmet medical need for patients struggling with erectile dysfunction.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | Fr.850.00K | 1 |
|
31 Jan 2023 |
| Convertible Note | $1.30M | 1 | Foundation for Technological Innovation (FIT) | 01 Dec 2020 |
| Seed Round | Fr.3.00M | 3 |
|
26 Jun 2019 |
| Debt Financing | Fr.100.00K | 1 | Foundation for Technological Innovation (FIT) | 30 Nov 2017 |
| Grant | Fr.20.00K | 1 |
|
05 Sep 2017 |
No recent news or press coverage available for Comphya.
We care about your data, and we'd love to use cookies make your experience better.
